What is Essential Thrombocythemia

Essential Thrombocythemia is a rare chronic blood cancer characterized by the bone marrow producing an excessive number of platelets, which increases the risk of abnormal blood clotting or, paradoxically, bleeding. While many individuals with Essential Thrombocythemia lead long lives with proper management, the condition requires lifelong monitoring by a hematologist to mitigate risks of thrombosis and disease progression.

What happens in the body with Essential Thrombocythemia?

In patients with Essential Thrombocythemia, the body’s blood-forming system malfunctions. The bone marrow produces too many megakaryocytes—the cells that create platelets—leading to a state called thrombocytosis. This excess of platelets can cause blood to become "sticky," potentially obstructing blood vessels (thrombosis). Conversely, if platelets are dysfunctional, patients may experience bleeding or easy bruising. The primary affected system is the hematopoietic (blood-forming) system, which impacts cardiovascular health and systemic energy levels.

Who is typically affected by Essential Thrombocythemia?

Essential Thrombocythemia is classified as a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). It is a rare condition, with an estimated prevalence of 1 to 24 per 100,000 individuals globally. While it can occur at any age, it is most frequently diagnosed in individuals between the ages of 50 and 70, though it is increasingly identified in younger adults. Data from the DiseaseMaps.org community reflects this, with 325 members currently sharing their lived experiences with the condition.

What are the key clinical indicators?

Patients with Essential Thrombocythemia often report a range of symptoms that impact daily quality of life. Common clinical features include:

• Persistent fatigue and exhaustion


• Unexplained weight loss


• Bone pain, particularly in the limbs


• Visual disturbances such as blurry vision or migraines


• Frequent bleeding, easy bruising, or nosebleeds

What differentiates Essential Thrombocythemia from other conditions?

Unlike secondary thrombocytosis, where platelet counts rise due to an external cause like infection or iron deficiency, Essential Thrombocythemia is a primary disorder of the bone marrow. It is often distinguished by specific genetic mutations—most notably in the JAK2, CALR, or MPL genes—which help hematologists confirm the diagnosis and distinguish it from other myeloproliferative neoplasms like Polycythemia Vera.

Next steps

• Consult a board-certified hematologist to discuss your specific blood count trends and mutation status.


• Join the Essential Thrombocythemia community on DiseaseMaps.org to connect with others sharing similar health journeys.


• Adhere strictly to prescribed medications like Hydrea or aspirin as directed to reduce the risk of clot formation.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Essential Thrombocythemia


• Orphanet: Essential Thrombocythemia (ORPHA:3335)


• OMIM (Online Mendelian Inheritance in Man): Entry #187950


• MPN Research Foundation: Understanding Essential Thrombocythemia